# OptiLung

> OptiLung is a medical device startup creating the new standard for artificial lung technology. We engineer a more blood-compatible, clot-resistant ECMO (Extracorporeal Membrane Oxygenation) blood oxygenator designed to reduce hemolysis, minimize clotting, and improve device reliability for critically ill patients.

OptiLung's platform technology uses biomimetic vascular network architecture — blood flows through carefully designed internal channels rather than around bundled hollow fibers, as in conventional oxygenators. The device is manufactured as a single part from a single material in an almost entirely automated process, eliminating the manual assembly steps found in conventional oxygenator manufacturing.

Key facts:
- ECMO costs the healthcare system $15B annually, with daily patient costs up to $40,000
- Over 13,000 ECMO runs per year in the US
- OptiLung addresses reduced hemolysis, reduced clotting, and improved manufacturing reliability
- The platform is scalable to other blood-gas exchange applications including cardiopulmonary bypass and extracorporeal carbon dioxide removal
- Affiliated with Southwest Pediatric Device Consortium and Texas Medical Center Innovation Accelerator

## Company Info

- [Homepage](https://opti-lung.com/)
- [LinkedIn](https://www.linkedin.com/company/optilung/)
- Contact: info@opti-lung.com

## Sections

- [About ECMO](https://opti-lung.com/#about)
- [Technology](https://opti-lung.com/#technology)
- [Impact](https://opti-lung.com/#impact)
- [Our Story](https://opti-lung.com/#story)
- [Contact Us](https://opti-lung.com/#invest)